The DOI matches its Crossref record.
Modulation of carbonic anhydrase activity and its applications in therapy
Abstract
By catalysing a very simple physiological reaction, the hydration of carbon dioxide (CO2) to bicarbonate (HCO3-) and a proton (H+), carbonic anhydrases (CAs), of which five genetically distinct families (α – ϵ) are presently known, are fundamental enzymes in all organisms over the phylogenetic tree. In vertebrates, including humans, the 14 different α-CA isozymes presently known are involved in a host of physiological and pathological processes and modulation of their activity by means of specific inhibitors or activators leads to important pharmacological responses. CA inhibitors (CAIs) – systemic or topically acting – are clinically used ophthalmologic drugs for the management of glaucoma, cystoid macular oedema and retinopathies of diverse nature, being used alone or in combination therapies with many other agents. Topiramate (TPM) and zonisamide are widely used antiepileptics possessing a complex mechanism of action, in which CA inhibition plays a major role. Other neurological or neuromuscular disorders also make use of agents such as acetazolamide, methazolamide, ethoxzolamide or dichlorophenamide, in addition to the classical CAIs. CA activators on the other hand may lead to novel therapies in the treatment of cognitive disorders. Important advances were recently accomplished in the design of CA V-targeted inhibitors, with potential use as antiobesity agents that inhibit a critical step in lipogenesis in which the mitochondrial isozyme V is involved. Isozymes CA IX and CA XII play important roles in pH regulation, cell adhesion, proliferation and differentiation in hypoxic tumours and constitute conceptually novel targets for anticancer therapies. Indeed, many sulfonamide and sulfamate potent CA IX inhibitors were reported, which may open new vistas for such antitumour therapies. Several CA isozymes are complexed with proteins involved in anion transport, such as anion exchangers (AE1) or Na+/HCO3- cotransporter proteins (NBC1 and NBC3), forming metabolons, in which the enzymatic activity of each protein is enhanced by its companion. The understanding of the biochemical mechanisms involved in such interactions may also lead to important novel pharmacological applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Alterio, V., Di Fiore, A., D’Ambrosio, K., Supuran, C. T., & De Simone, G. (2012) · Chemical Reviews · doi:10.1021/cr200176r · Cited by 1,238
Self-citationRivera, C., Voipio, J., & Kaila, K. (2005) · The Journal of Physiology · doi:10.1113/jphysiol.2004.077495 · Cited by 428
Anticancer carbonic anhydrase inhibitors: a patent review (2008 – 2013)
Monti, S. M., Supuran, C. T., & De Simone, G. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.798648 · Cited by 265
Self-citationInnocenti, A., Zimmerman, S., Ferry, J., Scozzafava, A., & Supuran, C. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.06.073 · Cited by 50
Metadata
- Authors
- Scozzafava, A., Mastrolorenzo, A., & Supuran, C. T.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa Healthcare
- Published
- 2004-05
- Volume
- 14
- Issue
- 5
- Pages
- 667-702
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2106688214
- Cited by
- 163
- References
- 0
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of carbonic anhydrase activity and its applications in therapy. https://app.cochat.ai/papers/10.1517/13543776.14.5.667
- The paper
- Scozzafava, A., Mastrolorenzo, A., & Supuran, C. T. (2004). Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.14.5.667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.